Boehringer Ingelheim and Lilly Commence P-III EMPULSE Study to Evaluate

Shots: The P-III EMPLULSE study (NCT04157751) will evaluate clinical benefits safety and tolerability of Jardiance (empagliflozin, 10mg, PO) in ~500 patients hospitalized for acute heart failure who have been stabilized including patients both with and without T2D The P-III EMPULSE study will evaluate whether Jardiance will able alleviate symptoms associated with HF and improve outcomes […]Read More